First Follow-Up of Cardiac Amyloidosis Treated by Tafamidis, Evaluated by Absolute Quantification in Bone Scintigraphy.
ATTR, transthyretin-related [amyloidosis]
HMDP-99mTc, hydroxydimethylene diphosphonate–technetium-99m
IVS, interventricular septum
LVEF, left ventricular ejection fraction
NT-ProBNP, N-terminal pro–B-type natriuretic peptide
NYHA, New York Heart Association
SPECT, single-photon emission computed tomography
SUV, standardized uptake value
SUVmax, maximum standardized uptake value
chronic heart failure
hybrid imaging
treatment
Journal
JACC. Case reports
ISSN: 2666-0849
Titre abrégé: JACC Case Rep
Pays: Netherlands
ID NLM: 101757292
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
20
03
2020
revised:
20
11
2020
accepted:
23
11
2020
entrez:
28
7
2021
pubmed:
29
7
2021
medline:
29
7
2021
Statut:
epublish
Résumé
Assessment of absolute myocardial hydroxydimethylene diphosphonate-technetium-99m uptake using standardized uptake value with a single-photon emission computed tomography-computed tomography cadmium zinc telluride camera (Discovery NM/CT 670CZT, GE Healthcare, Chicago, Illinois) in a patient with cardiac transthyretin-related amyloidosis treated with tafamidis showed a decrease in hydroxydimethylene diphosphonate cardiac uptake. This imaging technique should be helpful in monitoring therapy and evaluating prognosis. (
Identifiants
pubmed: 34317486
doi: 10.1016/j.jaccas.2020.11.036
pii: S2666-0849(20)31436-4
pmc: PMC8305621
doi:
Types de publication
Journal Article
Langues
eng
Pagination
133-135Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
Circulation. 2016 Jun 14;133(24):2404-12
pubmed: 27143678
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929